Table A. SARS-CoV-2 Variants Currently or Recently Circulating in the United States and Their Susceptibility to Anti-SARS-CoV-2 Monoclonal Antibodies
Last Updated: March 6, 2023
See the Guidelines Archive for information on bamlanivimab plus etesevimab, casirivimab plus imdevimab, and variants that were previously circulating in the United States.
WHO Label and Pango Lineage | BEB | TIX Plus CIL | SOT | |||
---|---|---|---|---|---|---|
In Vitro Susceptibilitya | Anticipated Clinical Activity | In Vitro Susceptibilitya | Anticipated Clinical Activity | In Vitro Susceptibilitya | Anticipated Clinical Activity | |
Omicron BA.5 | No change | Active | Moderate reduction | Active | Marked reduction | Unlikely to be active |
Omicron BA.4.6/BF.7 | No change | Active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active |
Omicron BQ.1 | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active |
Omicron BQ.1.1 | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active |
Omicron XBB | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active |
Omicron XBB.1.5 | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active | Marked reduction | Unlikely to be active |
a This information is based on the fold reduction in susceptibility reported in the FDA EUAs1-3 and in vitro neutralization studies.4-9
Key: BEB = bebtelovimab; CIL = cilgavimab; EUA = Emergency Use Authorization; FDA = Food and Drug Administration; SOT = sotrovimab; TIX = tixagevimab; WHO = World Health Organization |
References
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization (EUA) of sotrovimab. 2022. Available at: https://www.fda.gov/media/149534/download.
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab). 2023. Available at: https://www.fda.gov/media/154701/download.
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for bebtelovimab. 2022. Available at: https://www.fda.gov/media/156152/download.
- Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023;388(1):89-91. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36476720.
- Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023;186(2):279-286.e8. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36580913.
- Takashita E, Yamayoshi S, Halfmann P, et al. In vitro efficacy of antiviral agents against Omicron subvariant BA.4.6. N Engl J Med. 2022;387(22):2094-2097. Available at: https://pubmed.ncbi.nlm.nih.gov/36383452/.
- Wang Q, Li Z, Ho J, et al. Resistance of SARS-CoV-2 Omicron subvariant BA.4.6. to antibody neutralisation. Lancet Infect Dis. 2022;22(12):1666-1668. Available at: https://pubmed.ncbi.nlm.nih.gov/36328002/.
- Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387(5):468-470. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35857646.
- Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608(7923):603-608. Available at: https://pubmed.ncbi.nlm.nih.gov/35790190/.